This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-09 and is reviewed periodically as new material appears.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Recent research shows promising results in mortality and morbidity reductions when a state integrates drug monitoring programs with health information technologies and shares data through a centralized platform. The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act was introduced by the US House of Representatives on June 22, 2018, and was advanced on June 22, 2018. The bill includes Medicare and Medicaid reform in order to improve treatment, recovery, and prevention efforts while also strengthening the fight against synthetic drugs like fentanyl. In September 2018, the US Senate approved the SUPPORT for Patients and Communities Act (H.R. 6). The committee reached a final agreement on terms of the bill on September 25, 2018. The final agreement included provisions from multiple other acts, such as The Opioid Crisis Response Act of 2018, The Helping to End Addiction and Lessen (HEAL) Substance Use Disorders Act of 2018, and the Synthetics Trafficking and Overdose Prevention (STOP) Act of 2018. The House and The Senate passed the final draft on September 28 and October 3, respectively. President Donald Trump signed the package into law on October 28, 2018. In July 2019, English multinational consumer goods corporation Reckitt Benckiser, parent of US pharmaceutical company Indivior, agreed to pay $1.4 billion to the U.S.
==== Extramural researchers and scientists ==== Important stakeholders of the NIH funding policy include researchers and scientists. Extramural researchers differ from intramural researchers in that they are not employed by the NIH but may apply for funding. Throughout the history of the NIH, the amount of funding received has increased, but the proportion to each IC remains relatively constant. The individual ICs then decide who will receive the grant money and how much will be allotted. Policy changes on who receives funding significantly affect researchers. For example, the NIH has recently attempted to approve more first-time NIH R01 applicants or the research grant applications of young scientists. To encourage the participation of young scientists, the application process has been shortened and made easier. In addition, first-time applicants are being offered more funding for their research grants than those who have received grants in the past.
== Mass defect == The mass defect used in nuclear physics is different from its use in mass spectrometry. In nuclear physics, the mass defect is the difference in the mass of a composite particle and the sum of the masses of its component parts. In mass spectrometry the mass defect is defined as the difference between the exact mass and the nearest integer mass. The Kendrick mass defect is the exact Kendrick mass subtracted from the nearest integer Kendrick mass. Mass defect filtering can be used to selectively detect compounds with a mass spectrometer based on their chemical composition.
For example, the Ranunculaceae species, including Clematis and Ranunculus, produces an etaerio of achenes; Rubus species, including raspberry: an etaerio of drupelets; Calotropis species: an etaerio of follicles fruit; Annona species: an etaerio of berries. Some other broadly recognized species and their etaerios (or aggregations) are:
Sources: en.wikipedia.org
== Early life and education == Huttenlocher was born to two academic parents; her father, Peter, was a pediatric neurologist and her mother, Janellen, was a psychologist. She completed her Bachelor of Science degree at Oberlin College and her medical degree from Harvard Medical School. Following Harvard, she completed her training at Boston Children's Hospital and the University of California, San Francisco.
== External links == "Chain of Being" in the Dictionary of the History of Ideas The Great Chain of Being reflected in the work of Descartes, Spinoza & Leibniz. Archived 2008-08-28 at the Wayback Machine. Peter Suber, Earlham College, Indiana
== Other uses == Some Native American tribes use the hard outer shell of the pine nut as a bead for decorative purposes in traditional regalia and jewelry. In the Great Basin area of the US, collecting pine nuts is a protected right through state law and treaty. In northern California, pine nuts are collected from the grey pine or bull pine. Tribes burn designs into the hard shell, reflecting the same design they use in baskets; however, they are often left blank or burned to blacken. These are more often used in women's regalia and jewelry.
Meanwhile, the life expectancy for Japanese already now is more than 84 years, and for Monaco it is reported to be more than 89 years. It may not be possible to achieve further increases without development of new biomedical technologies and approaches. Searches of various equivalents of the elixir of youth happened yet in ancient times: people hoped to find a miraculous remedy in faraway territories, tried to use magic and alchemy. Scientific and technological attempts began at the end of the 19th century. For their intended purpose, all of them turned out to be inefficient at best, sometimes led to premature death, but they had many useful and sometimes unexpected consequences.
By the mid-2000s, Liebling had nearly disappeared from public life. He spent his days isolated in his parents' basement, trapped in a relentless cycle of addiction and self-destructive behavior. The toll of decades of substance abuse was evident in his skeletal frame, which was covered in sores and barely functioning, leading many to believe he was beyond redemption. This chapter of his life, which took an unexpected turn, became the subject of the documentary Last Days Here (2011), directed by Don Argott and Demian Fenton. Filmed over four years, the documentary follows Liebling, who is in his 50s and living in the basement of his parents' house in Alexandria, Virginia, as he battles severe drug addiction. His friend, manager, and longtime Pentagram fan Sean "Pellet" Pelletier took it upon himself to pull Liebling out of the abyss and get him back to music and a healthier life. Alongside Pelletier, the film features interviews with former Pentagram members, friends, Liebling's parents, and his then-girlfriend, Hallie. The documentary ends on a hopeful note; by 2010, Pentagram had returned to the stage, and Liebling was sober, married to Hallie, and expecting their first child. When Argott and Fenton first met Liebling, they had little hope that his story would lead anywhere. "Bobby was in such bad shape when Pellet introduced us to him that we didn't think his story would go anywhere. It really seemed like he was going to smoke himself to death in his parents' basement, something we weren't interested in documenting," Fenton recalled.
Sources: en.wikipedia.org
Guinness Draught, the standard draught beer sold in kegs (but exist also a texture-like version in widget cans and bottles): 4.1 to 4.3% alcohol by volume (ABV); the Extra Cold is served through a super cooler at 3.5 °C (38.3 °F). Guinness Original/Extra Stout: 4.2 or 4.3% ABV in Ireland and the United Kingdom, 4.1% in Germany, 5.0% in continental Europe and Scandinavia (such as Sweden), 4.8% in Namibia and South Africa, 5.6% in the United States and Canada, and 6% in Australia and Japan. Guinness Foreign Extra Stout: 7.5% ABV version sold in Europe, Africa, the Caribbean, Asia, and the United States. The basis is an unfermented but hopped Guinness wort extract shipped from Dublin, which is added to local ingredients and fermented locally. The strength can vary, for example, it is sold at 5% ABV in China, 6.5% ABV in Jamaica and East Africa, 6.8% in Malaysia, 7.5% in the United States, and 8% ABV in Singapore. In Nigeria a proportion of sorghum is used. Foreign Extra Stout is blended with a small amount of intentionally soured beer. Formerly, it was blended with beer that soured naturally as a result of fermenting in ancient oak tuns with a Brettanomyces population; it is now made with pasteurised beer that has been soured bacterially. It was previously known as West Indies Porter, then Extra Stout and finally Foreign Extra Stout. It was first made available in the UK in 1990. Guinness Special Export Stout, Commissioned by John Martin of Belgium in 1912. The first variety of Guinness to be pasteurised, in 1930. 8% ABV.
=== Adrian Shephard === Adrian Shephard is the protagonist of Half-Life: Opposing Force. He is a 22-year old corporal in the United States Marine Corps (USMC) stationed at the fictional Santego Military Base in Arizona who is mysteriously transferred to the Hazardous Environment Combat Unit (HECU), a special USMC unit. Three months after his transfer, he is sent to the Black Mesa Research Facility (BMRF) to defeat the Xenian invasion and summarily execute all BMRF personnel. However, the Bell Boeing V-22 Osprey transporting him is hit by a Xenian energy blast and crashes; he is rescued by a group of Black Mesa scientists, and due to never making it to his designated landing zone, Shephard remains unaware of the secret orders to kill all BMRF employees. Making his way through the facility while being observed by the G-Man, he eventually comes across a thermonuclear weapon brought in by the Central Intelligence Agency and deactivates it, but the G-Man later reactivates it, leading to the eventual destruction of Black Mesa. In the end, the G-Man reveals that he has successfully argued for Shephard's life, detaining him in some unknown void. The G-Man expresses a degree of respect for Shephard, offering praise for his ability to "adapt and survive against all odds" which "rather reminds [the G-Man] of [himself]". Shephard is briefly mentioned in Half-Life: Blue Shift, where a HECU marine grumbles about taking over some of Shephard's squad's duties.
The HIC of leaf water is variable during the biosynthesis, and the enrichment in the whole leaf can be described by the equation, △Dleaf = △De × ([1 − e−p]/P) The typical δD of bulk plant is around −160‰, while δDs for cellulose and lignin are −110‰ and −70‰ respectively.
The safety of aspartame has been studied since its discovery, and it is a rigorously tested food ingredient. Aspartame has been deemed safe for human consumption by over 100 regulatory agencies in their respective countries, including the US Food and Drug Administration (FDA), UK Food Standards Agency, the European Food Safety Authority (EFSA), Health Canada, and Food Standards Australia New Zealand.
== Detection == The polyhistidine-tag can also be used for detecting a protein via anti-polyhistidine-tag antibodies, which can be useful for subcellular localization, ELISA, western blotting and other immuno-analytical methods. Alternatively, in-gel staining of SDS-PAGE or native-PAGE gels with fluorescent probes bearing metal ions can be used for detection of a polyhistidine tagged protein.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。